ATB 346

Drug Profile

ATB 346

Alternative Names: ATB-346

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Antibe Therapeutics
  • Developer Antibe Therapeutics; Imperial College of Science, Technology and Medicine; McMaster University; Universita di Napoli Federico II; University of Calgary; William Harvey Research Institute
  • Class Antirheumatics; Nonsteroidal anti-inflammatories
  • Mechanism of Action Apoptosis stimulants; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Pain
  • Preclinical Intestinal cancer; Malignant melanoma; Periodontal disorders

Most Recent Events

  • 24 Feb 2017 ATB 346 licensed to Laboratoire Acbel in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan for commercialisation
  • 25 Oct 2016 Efficacy and adverse events data from a phase II trial for Pain released by Antibe Therapeutics
  • 23 Sep 2016 Pharmacodynamics data from in vitro and in vivo studies in Malignant melanoma released by Antibe Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top